In the treatment of type 2 diabetes (T2D), sodium-glucose co-transporter-2 (SGLT2) inhibitors or gliflozins, a new class of oral anti-diabetic drugs, and liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, are important drugs in glycemic control. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.